University of Melbourne — Publications

An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome.

Article

4577 Background: Prostate cancer (PCa) is the commonest male cancer in the Western world. Its biology and prognosis are heterogeneous and improved tools are needed to predict outcome more reliably. Here we studied the feasibility and clinical utility of whole blood mRNA expression array studies for this purpose. Methods: Whole blood samples were collected into PaxGene tubes between 08/2007 and 04/2008 from 100 PCa patients (pts): 31 good prognosis pts selected for active surveillance (AS) and 69 advanced castration resistant prostate cancer (CRPC) pts. RNA was extracted, amplified and biotinylated; unsupervised genome-wide expression profiles were analysed with HGU133plus2 (Affymetrix) microarrays and using Bayesian Latent Process Decomposition (LPD) analyses (Carrivick et al, 2006) in 94 patients; associations with outcome were studied. Results: LPD analysis of the whole blood mRNA expression data divided the pts into 4 separate groups (LPD1 to 4, with 10 unclassifiable pts). LPD1 (n=14) and LPD2 (n=18) consisted almost entirely of CRPC pts (14/14; 17/18); the single active surveillance patient in LPD2 had a rapidly rising PSA and required a prostatectomy. All the 4 groups included CRPC pts (LPD3:15/31; LDP4: 12/21); LPD1 CRPC pts had poorer overall survival (median 10.7 months, CI-95% 4.2-17.2) than CRPC pts in LPD2 to 4 (median 26.5 months, CI-95% 18.1-34.9, p=0.00007). Other baseline characteristics associated with LPD1 were increased number of treatment lines, worse performance status, and a higher proportion of detectable TMPRSS2/ERG transcripts. Group 1 membership remained the strongest prognostic factor in a multivariate analysis (HR 5.0, CI-95% 2.1-11.9, p = 0.0002). Gene signatures in the poor prognosis LPD group 1 were associated with increased CD71+ early erythroid cells and a decreased B-cell and T-cell immune response. A 9-gene signature (TERF2IP, TMCC2, GABARAPL2, SNCA, RIOK3, TFDP1, SLC4A1, HMBS, STOM) classified samples as group LPD 1 with a very low misclassification rate (0.012). Conclusions: PCa patient outcome can be predicted using gene expression signatures from peripheral blood.

David Olmos, J. W. Clark, Daniel Brewer et al. 2011

Publications

Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study

Supplementary Figure S3 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model

Immunological characteristics of Mycobacterium tuberculosis subunit vaccines immunized through different routes

Prediction of the load-shortening curve of CFST columns using ANN-based models

Supplementary Figure S2 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

Machine learning-based method using adaptive differential evolution for optimizing nonlinear steel frames

Performance of New Connections for Robustness Design of Cold-Formed Steel Structures

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Advanced Analysis of Steel Frames

Trefoil Factor 3 Is Oncogenic and Mediates Anti-Estrogen Resistance in Human Mammary Carcinoma

Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing

Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn’s disease patients

Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma

wo guo zhong xiao qi ye quan mian feng xian guan li ti xi tan tao

Supplementary Methods and References from UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas

An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome.

Establishing barriers and enablers to nurse-enabled, subcutaneous therapy self-administration programs for myeloma patients: Protocol for a qualitative, descriptive study (Preprint)

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Publications

Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study

Supplementary Figure S3 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model

Immunological characteristics of Mycobacterium tuberculosis subunit vaccines immunized through different routes

Prediction of the load-shortening curve of CFST columns using ANN-based models

Supplementary Figure S2 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

Machine learning-based method using adaptive differential evolution for optimizing nonlinear steel frames

Performance of New Connections for Robustness Design of Cold-Formed Steel Structures

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Advanced Analysis of Steel Frames

Trefoil Factor 3 Is Oncogenic and Mediates Anti-Estrogen Resistance in Human Mammary Carcinoma

Clonal independence of &lt;i&gt;JAK2&lt;/i&gt; and &lt;i&gt;CALR&lt;/i&gt; or &lt;i&gt;MPL&lt;/i&gt; mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing

Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn’s disease patients

Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma

wo guo zhong xiao qi ye quan mian feng xian guan li ti xi tan tao

Supplementary Methods and References from UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas

An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome.

Establishing barriers and enablers to nurse-enabled, subcutaneous therapy self-administration programs for myeloma patients: Protocol for a qualitative, descriptive study (Preprint)

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing